CSL Behring adopts FIDA for accurate characterization of molecular interactions based on direct, in-solution measurements
“In benchmarking tests, FIDA has enabled CSL Behring to assess protein binding in solution with results comparable to current in-house technologies based on surface coupling of one binding partner. We are looking forward to using FIDA for the molecular interaction characterization of our innovative plasma-derived drug candidates.” Giuseppina Fascellaro, Ph.D., Research Scientist, CSL Behring, Bern, [click].
Direct detection and quantification of proteins under native conditions
Mitigate immunogenicity with fast development of specific assays
Faster drug development – higher safety – better efficacy
Easy protocols – results in 5 min. – built-in quality control
Flow Induced Dispersion Analysis (FIDA) is a new proprietary technology developed for quantification and characterization of proteins (including biologics), early detection of immune responses (including immunogenicity testing) and affinity assessment. FIDA is characterized by being fast (minutes), requiring very small sample amounts (nL-mL), and being exceptionally tolerant to the sample matrix. Contrary to most other procedures, the FIDA methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development is therefore avoided. The unique features of FIDA enable characterization and quantification in native (biorelevant) environments and in-built assay quality control and automation.